Allegra Sales Decline Will Not Prompt OTC Switch, Aventis Says
This article was originally published in The Tan Sheet
Executive Summary
Decreasing Allegra sales in the face of increased competition from OTC antihistamines will not lead Aventis to pursue a switch for the drug, the firm stated during an Oct. 30 call on third-quarter results
You may also be interested in...
Allegra Faces Increasing Challenges In Rx Drug Arena
Obstacles to marketing second generation, non-sedating antihistamine Allegra effectively as a prescription drug have escalated substantially in the past year, according to Aventis
Allegra Faces Increasing Challenges In Rx Drug Arena
Obstacles to marketing second generation, non-sedating antihistamine Allegra effectively as a prescription drug have escalated substantially in the past year, according to Aventis
Allegra Faces Increasing Challenges In Rx Drug Arena
Obstacles to marketing second generation, non-sedating antihistamine Allegra effectively as a prescription drug have escalated substantially in the past year, according to Aventis